In a previous study, we demonstrated the potent anti-cancer activity and the safety of an immunomodulatory RNA (immRNA), a novel RIG-I agonist composed of a hairpin RNA molecule with 5' triphosphate, delivered by red blood cell-derived extracellular vesicles (RBCEVs) for the treatment of primary tumors and lung metastasis of breast cancer 26. Here, RIGI is linked to cancer.